ClinicalTrials.gg
Sign In
Enrolling by invitationNCT07204665EUCOBSUpdated Oct 2, 2025

This Study Has Been Designed to Support the Working Hypothesis That Emergency Surgery in a Colon Obstruction Neoplasm is Better Than Stent Bridge Due to Better Oncological Outcomes, Analyzing the Importance of ERAS Programs in Emergency Colon Obstruction Surgery.

An observational study in Colon Obstruction, sponsored by Universidad de Zaragoza. Enrolling by invitation at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Universidad de Zaragoza · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as enrolling by invitation.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

This study has been designed to support the working hypothesis that emergency surgery in a colon obstruction neoplasm is better than stent bridge due to better oncological outcomes. The primary objective is to analyse the importance of ERAS program implementation in emergency colon obstruction surgery

02

Conditions studied

  • Colon Obstruction
03

In context

Lead sponsor

Universidad de Zaragoza is the lead sponsor of 111 studies on the registry; 18 are open to participants now.

Browse Universidad de Zaragoza studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (aged >18 years) with a diagnosis of Malignant obstruction colorectal cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult patients (aged >18 years) with a diagnosis of Malignant obstruction colorectal cancer. will be obtained from all subjects who will participate in the study voluntarily.
  • , II and III
  • No more than 5 days from symptoms onset.
  • Absence of proximal colon severe dilatation( no more than 8 centimeters), severe malnutrition.
  • No Inmunocompromised patients
  • Patients suffer from segmentary colectomy, with or without anastomosis with o witjhout lateral ileostomy
  • Patients suffer from Hartmann procedure.

Exclusion criteria

Exclusion criteria:

  • Patient refusal.
  • Patients under 18 years of age.
  • Stent placement
  • ICU stay more than 2 days
  • Peritonitis
  • Out of protocol if patient would need total parenteral nutrition(NPT) during postoperative or Clavien-Dindo more or equal than II.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Urgent

    Patients with urgent surgery

  • Elective

    Patients with elective surgery

06

What researchers measure

Primary outcomes

  1. Postoperative complications

    The primary objective is to analyse the importance of ERAS program implementation in emergency colon obstruction surgery

    Time frame: From enrollment to 90 days

Secondary outcomes

  1. 1 year survival analysis

    1 year survival analysis

    Time frame: 360 days after surgery

  2. Overall survival

    Overall survival

    Time frame: 365 days after surgery

  3. disease-related survival

    disease-related survival

    Time frame: 365 days after surgery

  4. disease-free survival

    disease-free survival

    Time frame: 365 days after surgery

  5. Relationship between stent bridge and colon perforation

    Relationship between stent bridge and colon perforation

    Time frame: 60 days after stent placement

07

Study locations

1 site
  • Hospital de Urduliz
    Bilbao, Vizcaya 49600, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Apr 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 2, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Apr 30, 2026
CompletionEst.
Apr 30, 2027
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07204665
Lead sponsor
Universidad de Zaragoza
Responsible party
Jose-M Ramirez (Full Professor, Universidad de Zaragoza) — Principal investigator
First posted
Oct 2, 2025
Start date
Jul 1, 2025
Primary completion
Apr 30, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 2, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Universidad de Zaragoza →

Start the discussion